# Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma

> **NCT01339039** · PHASE1 · TERMINATED · sponsor: **Patrick Y. Wen, MD** · enrollment: 26 (actual)

## Conditions studied

- High Grade Glioma: Glioblastoma (GBM)
- High Grade Glioma: Gliosarcoma
- Anaplastic Astrocytoma (AA)
- Anaplastic Oligodendroglioma (AO)
- Mixed Anaplastic Oligoastrocytoma (AOA)

## Interventions

- **DRUG:** Plerixafor
- **DRUG:** Plerixafor
- **DRUG:** Bevacizumab
- **DRUG:** Plerixafor
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT01339039
- **Lead sponsor:** Patrick Y. Wen, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-12
- **Primary completion:** 2014-04
- **Final completion:** 2017-04-08
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Low accrual rate
- **Last updated:** 2017-11-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01339039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01339039, "Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT01339039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*